University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Papers in Veterinary and Biomedical Science

Veterinary and Biomedical Sciences,
Department of

6-2011

Immune Evasion of Porcine Reproductive and Respiratory
Syndrome Virus through Glycan Shielding Involves both
Glycoprotein 5 as Well as Glycoprotein 3
Hiep Vu
University of Nebraska-Lincoln, hiepvu@unl.edu

Byungjoon Kwon
University of Nebraska - Lincoln

Kyoung-Jin Yoon
Iowa State University, kyoon@iastate.edu

William W. Laegreid
University of Illinois at Urbana-Champaign, wlaegrei@uwyo.edu

Asit K. Pattnaik
University of Nebraska-Lincoln, apattnaik2@unl.edu
Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers
See next page for additional authors
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental
Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons,
Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and Pathobiology
Commons

Vu, Hiep; Kwon, Byungjoon; Yoon, Kyoung-Jin; Laegreid, William W.; Pattnaik, Asit K.; and Osorio, Fernando
A., "Immune Evasion of Porcine Reproductive and Respiratory Syndrome Virus through Glycan Shielding
Involves both Glycoprotein 5 as Well as Glycoprotein 3" (2011). Papers in Veterinary and Biomedical
Science. 213.
https://digitalcommons.unl.edu/vetscipapers/213

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Hiep Vu, Byungjoon Kwon, Kyoung-Jin Yoon, William W. Laegreid, Asit K. Pattnaik, and Fernando A. Osorio

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
vetscipapers/213

JOURNAL OF VIROLOGY, June 2011, p. 5555–5564
0022-538X/11/$12.00 doi:10.1128/JVI.00189-11
Copyright © 2011, American Society for Microbiology. All Rights Reserved.

Vol. 85, No. 11
Used by permission

Immune Evasion of Porcine Reproductive and Respiratory Syndrome
Virus through Glycan Shielding Involves both Glycoprotein
5 as Well as Glycoprotein 3䌤
Hiep L. X. Vu,1 Byungjoon Kwon,1 Kyoung-Jin Yoon,2 William W. Laegreid,3
Asit K. Pattnaik,1 and Fernando A. Osorio1*
Nebraska Center for Virology and School of Veterinary Medicine and Biomedical Sciences, University of Nebraska—Lincoln,
Lincoln, Nebraska1; Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames,
Iowa2; and Department of Veterinary Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois3
Received 27 January 2011/Accepted 7 March 2011

Passive administration of porcine reproductive and respiratory syndrome virus (PRRSV) neutralizing
antibodies (NAbs) can effectively protect pigs against PRRSV infection. However, after PRRSV infection, pigs
typically develop a weak and deferred NAb response. One major reason for such a meager NAb response is the
phenomenon of glycan shielding involving GP5, a major glycoprotein carrying one major neutralizing epitope.
We describe here a type II PRRSV field isolate (PRRSV-01) that is highly susceptible to neutralization and
induces an atypically rapid, robust NAb response in vivo. Sequence analysis shows that PRRSV-01 lacks two
N-glycosylation sites, normally present in wild-type (wt) PRRSV strains, in two of its envelope glycoproteins,
one in GP3 (position 131) and the other in GP5 (position 51). To determine the influence of these missing
N-glycosylation sites on the distinct neutralization phenotype of PRRSV-01, a chimeric virus (FL01) was
generated by replacing the structural genes of type II PRRSV strain FL12 cDNA infectious clone with those
from PRRSV-01. N-glycosylation sites were reintroduced into GP3 and GP5 of FL01, separately or in combination, by site-directed mutagenesis. Reintroduction of the N-glycosylation site in either GP3 or GP5 allowed
recovery of in vivo and in vitro glycan shielding capacity, with an additive effect when these sites were
reintroduced into both glycoproteins simultaneously. Although the loss of these glycosylation sites has seemingly occurred naturally (presumably by passage through cell cultures), PRRSV-01 virus quickly regains these
glycosylation sites through replication in vivo, suggesting that a strong selective pressure is exerted at these
sites. Collectively, our data demonstrate the involvement of an N-glycan moiety located in GP3 in glycan shield
interference.

(13, 28, 31). GP5 forms a heterodimer with M, the membrane
protein (3, 27, 49). The GP5-M heterodimer is of cardinal
importance for the formation of viral particles (49). In addition, GP5 of both type I and type II PRRSVs contains a major
neutralizing epitope in its ectodomain (34–36, 46, 50). GP2,
GP3, and GP4 interact with each other to form a multiprotein
complex that is dispensable for viral particle formation yet
important for viral infectivity (11, 49). It has been reported
recently that GP2 and GP4 of the type II PRRSV strain FL12
interact with CD163, a receptor for PRRSV entry (11). GP4 of
the type I PRRSV strain Lelystad contains a neutralizing
epitope located at the hypervariable region spanning amino
acids 40 to 79 (32, 43). There are several lines of evidence for
the existence of neutralizing epitopes in other minor GPs of
PRRSV; however, the locations of these epitopes have not
been mapped (6, 19, 22).
Pigs exposed to PRRSV develop a prolonged viremia followed by persistent infection in lymphoid tissues for extended
periods of time, suggesting that the host immune system does
not effectively function at rapidly eliminating the infection (2,
48). The pig’s response to PRRSV infection is characterized by
a meager induction of innate immunity, the slow appearance of
virus-specific gamma interferon (IFN-␥)-producing cells, and
the weak and delayed development of neutralizing antibodies
(NAbs) (1, 4, 26, 29). Passive transfer of NAbs to pigs prior to
challenge with the homologous virulent PRRSV strain results

Porcine reproductive and respiratory syndrome virus
(PRRSV) is the causative agent of an economically important
disease in swine characterized by late-term reproductive failure in pregnant sows and respiratory disorder in young pigs (9,
47). PRRSV, together with equine arteritis virus (EAV), lactate dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV), belongs to the family Arteriviridae in
the order Nidovirales (7). The virus is classified into 2 types,
type I (European) and type II (North American) based on the
genetic and antigenic differences among the PRRSV strains.
The viral genome consists of a positive-sense, single-strand
RNA molecule of ⬃15 kb that contains 9 open reading frames
(ORFs) (10, 30, 51). ORF1a and ORF1b encode nonstructural
proteins (NSPs) responsible for the replication and transcription of the viral genome (30, 39). ORF2a, ORF2b, and ORF3
to ORF7 encode 7 structural proteins, four of which are glycoproteins (GPs), namely, GP2, GP3, GP4, and GP5 (30, 39, 51).
GP5 is considered the major envelope glycoprotein, while
GP2, GP3, and GP4 are considered the minor glycoproteins
due to the relative abundance of these proteins on the virions
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in complete protection of the pigs against infection, demonstrating the important role of NAbs in protective immunity (25,
33). The stimulation of NAbs should therefore be considered
an important goal for PRRSV vaccine development.
As previously observed for viruses such as simian immunodeficiency virus (38), human immunodeficiency virus (45), influenza virus (44), hepatitis C virus (24), and Ebola virus (16),
PRRSV also relies on glycosylation modification of its envelope proteins to evade the host immune response (3, 15). Our
laboratory has previously demonstrated that removal of N-glycosylation sites surrounding the neutralizing epitope located in
GP5 of a PRRSV strain (FL12) renders the virus extremely
susceptible to antibody neutralization (3). More importantly,
the mutant viruses carrying glycosylation deletions in GP5 elicited significantly greater NAb responses than did the wild-type
(wt), fully glycosylated virus (3). While the effects of glycosylation of GP5 on NAb development had been demonstrated,
the role that glycosylation of other PRRSV proteins may play
on glycan shielding immune evasion is not known yet.
We found a type II PRRSV field isolate, herein designated
PRRSV-01, which is able to elicit an atypically rapid and robust NAb response in infected pigs. In addition, PRRSV-01 is
extremely susceptible to neutralization by several different heterologous antisera. Analysis of structural genes of PRRSV-01
revealed that the virus naturally lacks two N-glycosylation sites
in its envelope glycoproteins, one in GP3 at position 131 and
the other in GP5 at position 51. The objective of this study was
to investigate the influence of the absence of N-glycosylation
sites in GP3 and GP5 on the susceptibility of PRRSV-01 to
NAbs and its ability to induce NAb production.
MATERIALS AND METHODS
Cells, viruses, and antibodies. MARC-145 cells (20) were used for viral RNA
electroporation and virus propagation and titration. Swine monocyte-derived
macrophages were prepared as previously described (40) and used for examination of viremia levels and for isolation of virus from serum samples. The porcine
reproductive and respiratory syndrome virus (PRRSV) field isolate, designated
PRRSV-01, was isolated at the Iowa State University Veterinary Diagnostic
Laboratory (ISU-VDL) in 2001 from a case of PRRSV infection associated with
clinical disease. Monoclonal antibody specific for PRRSV nucleocapsid (N)
protein (SDOW-17) was purchased from the National Veterinary Services Laboratories (Ames, IA). Anti-mouse, Alexa Fluor 488-conjugated antibody was
purchased from Invitrogen (Eugene, OR). Anti-GP5 polyclonal antibody was
kindly provided by Carl Gagnon (University of Quebec, Montreal, Canada).
Anti-GP3 polyclonal antibody was previously described (14). Swine hyperimmunized antisera against PRRSV strains NSVL 97-7895, VR2332, MN184, and
Lelystad were prepared as previously described (33).
Construction of chimeric virus and mutants derived from it. Viral RNA
isolated from culture supernatant of field isolate PRRSV-01 was used as the
template for reverse transcription-PCR (RT-PCR) to obtain the entire structural genes and the 3⬘ untranslated region (3⬘UTR). The PCR product was
digested with EcoRV and PacI, and the released fragment containing most of
ORF2a, all of ORF3 to ORF7, and the 3⬘UTR was cloned into the pFL12
plasmid (41) using the same restriction enzyme sites to generate chimeric
clone pFL01 (see Fig. 3). Using pFL01 as a backbone, site-directed mutagenesis was carried out by overlap extension using PCR as described previously
(18) to reintroduce N-glycosylation sites into GP3 (to produce pFL01/GP3D131N), GP5 (to produce pFL01/GP5-S51N), or both of them simultaneously
(to produce pFL01/DM). The primers used to reintroduce N-glycosylation
sites into GP3 and GP5 are shown in Table 1.
In vitro transcription and electroporation. In vitro transcription and viral RNA
electroporation were done as previously described (3, 41). Briefly, plasmid containing full-length PRRSV genomes was digested with AclI. Purified, linear
DNA was used as the template for in vitro transcription reaction using the
mMESSAGE mMACHINE Ultra T7 kit per the manufacturer’s instructions

J. VIROL.
TABLE 1. Primers used to reintroduce the N-glycosylation sites
into GP3 and GP5
Protein

Primera

Nucleotide sequenceb (5⬘33⬘)

GP3

D131N For

GAGATATTTGGGATAGGGAATGTGA
GTAAAGTTTATG
CATAAACTTTACTCACATTCCCTATC
CCAAATATCTC

D131N Rev
GP5

S51N For
S51N Rev

a
b

GCTATGCGAGCTGAATGGCACAGAT
TGGCTG
CAGCCAATCTGTGCCATTCAGCTCGC
ATAGC

For, forward; Rev, reverse.
Mutated nucleotides are underlined.

(Ambion, Austin, TX) to generate the capped, viral RNA transcript. Subconfluent MARC-145 cells were trypsinized and resuspended in fetal bovine serum
(FBS)-free Dulbecco modified Eagle medium (DMEM) containing 1.25% (vol/
vol) dimethyl sulfoxide (DMSO) at a concentration of 6 ⫻ 106 cells/ml. Four
hundred microliters of cells was electroporated with approximately 5 g of in
vitro viral RNA transcript together with 5 g of carrier RNA isolated from naïve
MARC-145 cells using Bio-Rad Gene Pulser Xcell at 250 V and 950 F in a
4.0-mm cuvette. Electroporated cells were diluted in DMEM containing 10%
FBS and 1.25% DMSO and placed in a 60-mm tissue culture dish. When a clear
cytopathic effect (CPE) was observed, culture supernatant containing rescued
virus was collected and passed into naïve MARC-145 cells once or twice to obtain
enough virus stock for future studies.
Metabolic labeling and protein analysis. Metabolic labeling and protein analysis were done as previously described (3, 11). MARC-145 cells in 6-well plate
were infected with PRRSV at a multiplicity of infection (MOI) of approximately
0.1 50% tissue culture infectious dose (TCID50) per cell. At 36 h postinfection
(p.i.), the cells were washed with phosphate-buffered saline (PBS) (pH 7.4) and
starved in methionine- and cysteine-free DMEM for 1 h. The proteins were
radiolabeled with 0.6 ml of methionine- and cysteine-free DMEM containing 30
Ci of Expre35S35S protein labeling mix (NEN Life Sciences, MA) for 4 h. After
radiolabeling, cell lysates were prepared, and the viral GP3 or GP5 was immunoprecipitated using anti-GP3 or anti-GP5 antibodies, respectively. After that,
the precipitated proteins were subjected to peptide N-glycosidase F (PNGase F)
digestion (3). The proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detected by fluorography as described earlier (3, 11).
Viral growth kinetics and plaque morphology. MARC-145 cells were infected
with wt or mutant viruses at an MOI of 5. Aliquots of culture supernatants from
infected cells were collected at various time points postinfection, and virus titers
were determined and expressed as TCID50 per ml. Plaque morphology was
examined in MARC-145 cells as previously described (3).
Animal experiments. Twenty-four recently weaned piglets (of about 3 weeks of
age) purchased from a specific-pathogen-free herd certified not to have PRRSV
infection were allocated into six groups and accommodated in isolated biosafety
level 2 (BSL-2) rooms. Each group of pigs was separately infected with one of the
following viruses: FL12, PRRSV-01, FL01, FL01/GP3-D131N, FL01/GP5-S51N,
or FL01/DM. Likewise, three additional pigs were inoculated with PRRSV-01
for initial characterization of the immune response stimulated by this isolate. In
all cases, the pigs were injected intramuscularly with 105.0 TCID50 of virus
diluted in 2 ml of DMEM. Serum samples were collected periodically from all
animals until 49 days postinfection (76 days postinfection for the initial experimental inoculation with PRRSV-01, which is shown in Fig. 1) and stored in small
aliquots at ⫺80°C for serological and virological analyses.
Serum neutralization assay. Neutralizing antibody titers of serum samples
against a specific PRRSV studied were determined using a fluorescent focus
neutralization assay described previously (51). Heat-inactivated antisera were
diluted 2-fold serially in 50 l of DMEM supplemented with 5% FBS on a
96-well plate and then incubated with an equal volume (50 l) containing 100
TCID50 of challenge virus for 1 h at 37°C. The entire mixture of serum and virus
(100 l/well) was transferred to another 96-well plate containing confluent
MARC-145 cells that had been seeded 48 h earlier. The plate was further
incubated for 36 h at 37°C in a humidified atmosphere containing 5% CO2. The
expression of N protein was detected by indirect immunofluorescence assay using
anti-N monoclonal antibody SDOW-17, and the presence of PRRSV was ob-
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served with a fluorescence microscope. Neutralization titers were expressed as
the reciprocal of the highest dilution that showed 90% or greater reduction in the
number of fluorescent foci presenting in the control wells.
Statistical analysis. Before statistical analysis, the neutralization titers were
transformed into log base 2. One-way analysis of variance (ANOVA) was used to
evaluate the difference among the mean neutralization titers. After that, Tukey’s
honestly significant difference test was used for multiple comparison.

RESULTS
Identification and primary characterization of the PRRSV
field isolate PRRSV-01 that exhibits a unique neutralization
phenotype. During studies involving subtyping of porcine reproductive and respiratory syndrome virus (PRRSV) field isolates by cross-neutralization (unrelated investigations [data not
shown here]), we identified a PRRSV field isolate, herein designated PRRSV-01, that possesses a distinct phenotype in relation to this isolate’s susceptibility to antibody neutralization
and its ability to elicit neutralizing antibodies (NAbs).
PRRSV-01 was isolated at the Iowa State University Veterinary Diagnostic Laboratory (ISU-VDL) in 2001 from a case of
PRRSV infection associated with clinical disease. After
PRRSV-01 was isolated, it was subjected to at least 7 passages
in MARC-145 cells at ISU-VDL and then in our laboratory.
We have observed that the current PRRSV-01 isolate resulting
from those passages in MARC-145 cells was extremely susceptible to neutralization by different heterologous antisera. A
complete battery of reference antisera used in our laboratory
that are specific for different PRRSV strains, including
VR2332 (9), NSVL 97-7895 (41), MN184 (17), and Lelystad
(47), was able to neutralize PRRSV-01 at endpoint titers of
1:64 or greater (Fig. 1A). Interestingly, the antisera to VR2332
and MN184 neutralized PRRSV-01 at titers that were 2-fold
higher than the titers of each individual antiserum against its
respective homologous virus. After 3 naïve pigs were infected
with PRRSV-01, we verified that this PRRSV isolate was able
to mount an atypically rapid and robust homologous NAb
response in the infected pigs (Fig. 1B). NAbs were detected in
2 out of 3 pigs infected with PRRSV-01 as early as 14 days
postinfection (p.i.) and in all of the infected pigs at 21 days p.i.
In addition, the NAb titers quickly increased and reached titers
from 1:512 to 1:2,048 in all of the infected pigs at 42 days p.i.
Remarkably, the NAb titer in one of the PRRSV-01-infected
pigs reached a peak of 1:4,096 at 76 days p.i. (Fig. 1B). This
constitutes a unique NAb response upon experimental inoculation with wt PRRSV. In our experience, neutralization titers
above 1:128 in pigs infected with a wt PRRSV strain are rarely
seen (3) (see Fig. 5).
Analysis of PRRSV-01 structural genes indicates that this
isolate naturally lacks two N-glycosylation sites in the sequences of its envelope glycoproteins. The entire structural
region of the PRRSV-01 genome was amplified by RT-PCR
and sequenced (GenBank accession no. JF422072). Overall,
the structural region of the PRRSV-01 genome shares 92%
nucleotide identity with strain VR2332, the PRRSV type II
prototype and 64% with Lelystad, the type I prototype (data
not shown), thus confirming that PRRSV-01 belongs to type
II genotype of PRRSV. Analysis of structural genes of
PRRSV-01 revealed that the virus possesses alterations in the
N-glycosylation patterns of its envelope glycoproteins. GP3 of
type II PRRSV typically contains 7 potential N-glycosylation

FIG. 1. Neutralization phenotype of PRRSV-01. (A) Susceptibility
of PRRSV-01 to cross-neutralization by heterologous antisera. The
neutralizing activity of the indicated antiserum was separately measured against PRRSV-01 or against the homologous virus (i.e., the
virus used for immunization to prepare each of the reference antisera).
(B) Homologous neutralizing antibody (NAb) responses of pigs infected with PRRSV-01. Three recently weaned pigs (pigs 2533, 6180,
and 7368) were inoculated with PRRSV-01 as described in Materials
and Methods. Homologous neutralization titers of serum samples at
the indicated time (in days) postinfection (PI) are shown. Neutralization titers were expressed as the reciprocal of the highest dilution that
showed 90% or greater reduction in the number of fluorescent foci
presenting in the control wells.

sites, all of which are well conserved in different PRRSV
strains (Fig. 2A). Recent studies demonstrate that the site at
position 195 of PRRSV strain FL12 is not glycosylated (12).
PRRSV-01 GP3 lacks one potential N-glycosylation site compared to other PRRSV strains due to the N131D substitution
(Fig. 2A). The number of potential N-glycosylation sites on
GP5 of type II PRRSV strains may vary between 3 and 5 (Fig.
2B). While the N-glycosylation sites at N44 and N51 are well
conserved, the number and position of N-glycosylation sites
upstream of N44 are highly variable. PRRSV-01 GP5 harbors
3 N-glycosylation sites at positions N29, N32, and N44 (Fig.
2B). However, compared to FL12 and other wt PRRSV
strains, PRRSV-01 GP5 possesses an N51S substitution that
disrupts the N-glycosylation site at this position (Fig. 2B).
There are no changes in the N-glycosylation patterns in GP2
and GP4 of PRRSV-01 (data not shown).
To determine whether PRRSV-01 GP3 and GP5 actually
lack N-glycosylation sites, we examined the electrophoretic
mobility of the proteins on SDS-polyacrylamide gels. FL12
GP3 and GP5 were used for comparison. PRRSV-01 GP3
migrates to a position of ⬃40 kDa, which is about 2.5 kDa
more than for FL12 GP3 (Fig. 3B, compare lanes 1 and 11).
Likewise, PRRSV-01 GP5 migrates to a position of ⬃22 kDa,
which is also ⬃2.5 kDa less than for FL12 GP5 (Fig. 3C,
compare lanes 1 and 11), although PRRSV-01 GP5 contains
the same number of potential N-glycosylation sites as FL12
GP5 does (Fig. 2B). Since each N-glycan moiety contributes
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FIG. 2. PRRSV-01 virus naturally lacks two N-glycosylation sites in its envelope glycoproteins. Multiple-sequence alignments of GP3 (A) and
GP5 (B) collected from the NCBI database. Only regions that cover the potential N-linked glycosylation sites are shown. Asparagine (N) residues
that contain the potential N-glycosylation sites are shown in boldface type. Positions in the PRRSV-01 sequence where the glycosylation sites are
absent compared to other porcine reproductive and respiratory syndrome virus (PRRSV) strains are shown on a gray background.

⬃2.5 kDa to the protein mass (23), the results indicate that for
both GP3 and GP5 of PRRSV-01, each contains one N-glycan
moiety less than the corresponding proteins of strain FL12.
The results also suggest that 1 of the potential N-glycosylation
sites in GP5 of PRRSV-01 is not used for incorporation of the
N-glycan moiety.
Reverse genetic system for studying the influence of the
absence of N-glycan moiety on the neutralization phenotype of
PRRSV-01. It has been well documented that modification of
viral envelope proteins by glycosylation is one of the common
strategies viruses employ to evade the host immune system (8,
16, 24, 38, 44). We were therefore interested in studying the
possible influence of the altered glycosylation patterns in GP3
and GP5 of PRRSV-01 on the susceptibility of the virus to
antibody neutralization in vitro and on the ability of the virus to
mount a NAb response in vivo. To facilitate our study, a chimeric cDNA infectious clone (FL01) was generated by replacing most of ORF2a, the entire ORFs for ORF3 to ORF7, and
the 3⬘UTR of FL12 cDNA infectious clone (41) with the counterparts of PRRSV-01 (Fig. 3A). Using FL01 as a backbone,

N-glycosylation sites were separately introduced into the glycan-missing positions in GP3 and GP5 by mutating D131 in
GP3 and S51 in GP5 to N, respectively. A double mutant was
also generated by mutating D131 in GP3 and S51 in GP5 to N
simultaneously. Viable viruses were rescued from FL01 and
mutants derived from it. The structural genes of the rescued
viruses were amplified by RT-PCR and sequenced to confirm
the presence of desired mutations and the absence of any other
unplanned mutations (data not shown).
To ascertain that the N-glycosylation sites artificially introduced into GP3 and GP5 were used for incorporation of glycan
moieties, we examined the electrophoretic mobility of the proteins on SDS-polyacrylamide gels. As shown in Fig. 3B, GP3 of
FL01/GP3-N131D and FL01/DM migrated to a position of
⬃42 kDa, which is the same molecular mass as FL12 GP3.
Similarly, GP5 of FL01/GP5-S51N and FL01/DM migrated to
the same position as FL12 GP5 did (Fig. 3C). The results
indicated that additional molecular mass was added to GP3
and GP5 when artificial N-glycosylation sites were introduced
into these proteins. To confirm that the additional molecular
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FIG. 3. (A) Schematic representations of the genomes of chimeric virus FL01 and mutants derived from it. The letter “Y” and the numbers
below them represent potential N-glycosylation sites and their relative positions on the corresponding proteins. The absence of N-glycosylation
sites at position 131 in GP3 and position 51 in GP5 is highlighted by rectangular boxes. N-glycosylation sites that are artificially reintroduced to
the genome are shown with a lightning bolt symbol over the site. (B and C) Electrophoretic mobility of GP3 and GP5, respectively. MARC-145
cells were mock infected or infected with the indicated virus. At 36 h postinfection, proteins were radiolabeled as described in Materials and
Methods and immunoprecipitated with anti-GP3 antibodies (B) or anti-GP5 antibodies (C). The immunoprecipitated proteins were left untreated
(⫺) or were treated with PNGase F (⫹) and analyzed by electrophoresis on SDS-polyacrylamide gel. The approximate molecular masses (in
kilodaltons) of the marker proteins are identified to the left of the gel. The positions of fully glycosylated proteins (black triangles) and of the
protein species lacking one N-glycosylation site (white triangles) are shown to the right of the gel. Protein bands indentified by black arrows are
the products of PNGase F digestion.

weight was indeed due to the addition of glycan moieties,
proteins after precipitation with anti-GP3 and anti-GP5 antibodies were treated with peptide N-glycosidase F (PNGase F),
an enzyme that cleaves off all forms of N-linked oligosaccharides from glycoproteins. As shown in Fig. 3B and C, after
treatment with PNGase F, all of the proteins migrated to the
same position. These results indicated that the additional molecular mass was indeed due to the addition of N-glycan moieties into the proteins. Collectively, our results indicated that

the artificial N-glycosylation sites were used for incorporation
of glycan moieties.
Influence of the reintroduced N-glycosylation sites on viral
replication in vitro. We had previously reported that deletions of certain N-glycosylation sites in GP3 and GP5 of
PRRSV strain FL12 severely affected the replication of the
mutated virus in cell culture (3, 12). In the present study,
both PRRSV-01 and FL01 grew very efficiently in MARC-145
cells in spite of the absence of N-glycosylation sites in their
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FIG. 4. Effects of the absence of N-glycosylation sites in GP3 and
GP5 on the in vitro growth properties. (A) Single-step growth curves of
the indicated viruses upon infection of MARC-145 cells at an MOI of
5. Viral titers are expressed as means ⫾ standard errors of the means
(SEMs) (error bars) of data obtained from three independent experiments. (B) Plaque morphology in MARC-145 cells.

GP3 and GP5 (Fig. 4). We asked whether introduction of
N-glycosylation sites into the glycan-missing positions of FL01
would have any effects on the viral growth properties. To this
end, growth kinetics was examined in MARC-145 cells. Overall, no significant difference in growth kinetics was observed
among the viruses (Fig. 4A). All of the viruses reached their
peak viral titers at times ranging from 24 to 48 h p.i., and the
titers gradually declined thereafter. The similar growth kinetics
for FL01 and mutants derived from it suggested that reintro-

ducing N-glycosylation sites into the FL01 genome did not
affect the efficiency of viral replication in vitro. Plaque morphology was also examined in MARC-145 cells. As shown in
Fig. 4B, all of the viruses were able to generate clear and
distinct plaques. Plaques generated by FL01 and FL01/GP3D131N were almost similar in size, and the sizes of their
plaques were intermediate between the plaques generated by
PRRSV-01 and FL12. Plaques generated by FL01/GP5-S51N
and FL01/DM were slightly smaller than those generated by
FL01.
Influence of the reintroduced N-glycosylation sites on the
susceptibility to antibody neutralization in vitro. We sought to
study the influence of the modification of N-glycosylation sites
on the susceptibility of FL01 to antibody neutralization. For
reference, we used serum samples collected from 4 different
pigs that had been infected with FL01. Neutralizing activities
of these antisera were separately measured against viruses with
different N-glycosylation patterns. As shown in Table 2, the
FL01-specific antisera could barely neutralize FL12 in spite of
the fact that the genomes of FL01 and FL12 share the same
nonstructural region. Conversely, the neutralization titers of
the FL01-specific sera measured against PRRSV-01 were not
significantly different from the titers measured against FL01,
the homologous virus, although the two viral genomes differ in
their nonstructural portions. Neutralization titers of the sera
were significantly reduced when measured against FL01/GP5S51N, the virus that contains the reintroduced N-glycosylation
site in its GP5. This result corroborates our previous finding
which indicated the importance of N-glycan at N51 in GP5 of
PRRSV on the susceptibility of the virus to antibody neutralization (3). Strikingly, neutralization titers were also significantly reduced when measured against FL01/GP3-D131N.
Neutralization titers were further reduced when measured
against FL01/DM, suggesting an additive effect of N-glycans in
GP3 and GP5. Collectively, our results indicate that the absence of N-glycans in GP3 and GP5 of PRRSV-01 is responsible for the enhanced susceptibility of this viral isolate to
antibody neutralization in vitro.
Influence of the reintroduced N-glycosylation sites on the
ability to elicit NAb response in vivo. We inoculated six different groups of recently weaned pigs with viruses containing
different glycosylation patterns to study the influence of the
reintroduced N-glycosylation sites on the ability to elicit neutralizing antibody response in vivo (Fig. 5). First, we measured
neutralizing activities of all serum samples taken at different

TABLE 2. Susceptibility of different PRRSV strains to antibody neutralization in vitro
Neutralization titerb measured against the following virus:

Serum samplea
FL01

1
2
3
4
Geometric mean
a

PRRSV-01

2,048
8,192
1,024
1,024

2,048
4,096
2,048
2,048

2,048 A

2,435.5 A

FL12

8
8
ⱕ4
8
4.8 B

FL01/GP3-D131N

256
1,024
256
128
304.4 C

FL01/GP5-S51N

FL01/DM

128
256
256
256

64
64
64
32

215.3 CD

53.8 D

Serum samples were obtained from pigs that had been infected with FL01 at 49 days postinfection (p.i.).
Neutralization titers were expressed as the reciprocal of the highest dilution that showed 90% or greater reduction in the number of fluorescent foci presenting in
the control wells. Means with different letters (A to D) are significantly different (P ⬍ 0.05).
b
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TABLE 3. Neutralizing activities of serum samples measured
against FL01/DMa
Neutralization
titerb

Virus

PRRSV-01..................................................................................... 98.7
FL01...............................................................................................128
FL01/GP3-D131N ........................................................................ 58.7
FL01/GP5-S51N............................................................................ 64
FL01/DM....................................................................................... 45.3
a
The serum samples were from pigs infected with different viruses, and the
samples were collected at 49 days p.i.
b
The neutralization titers were expressed as the geometric means of endpoint
titers (n ⫽ 4 pigs per group). The differences observed among the means of titers
were not statistically significant (P ⬎ 0.05 by one-way ANOVA).

FIG. 5. Kinetics of NAb response to homologous viruses. Each
group of 4 recently weaned pigs was separately inoculated with the
indicated virus as described in Materials and Methods. The neutralizing activities of serum samples at the indicated time (in days)
postinfection (PI) were measured against homologous virus (i.e.,
the same virus used for infection). Neutralization titers are expressed as means ⫾ SEMs.

time points, ranging from 7 to 49 days p.i. against the corresponding homologous viruses (the term homologous refers to
the virus used for infection in each case). Pigs infected with
FL01 and PRRSV-01 mounted very early and robust NAb
responses. Homologous NAbs were detected in pigs infected
with these 2 viruses at times as early as 14 days p.i., and the
antibody titers quickly increased and reached the mean titers
of between 1:2,048 and 1:4,096 at 49 days p.i. There were no
significant differences in the kinetics of homologous NAb responses between pigs infected with FL01 and pigs infected with
PRRSV-01. In sharp contrast, homologous NAbs were not
detected in pigs infected with FL01/DM and FL12 until 28 days
p.i. At 49 days p.i., the mean neutralization titer of FL01/DMinfected pigs was only 1:45, which was ⬃76-fold lower than the
homologous titers of pigs infected with FL01 at the same time
p.i. Homologous NAb induction in pigs infected with FL01/
GP3-D131N and FL01/GP5-S51N was intermediate between
FL01/DM and FL01. These results demonstrate that the Nglycan moieties in both GP3 and GP5 of PRRSV-01 affect the
ability of the virus to elicit a homologous NAb response.
Next, we wanted to study the effects of N-glycan moieties
on the NAb response against FL01/DM, the fully glycosylated virus. Antisera from pigs infected with hypoglycosylated viruses possessed greater neutralizing activities against
FL01/DM than did the antisera from FL01/DM-infected pigs
(Table 3). However, the differences in neutralizing activities in
the different groups of pigs were not statistically significant.
Simultaneous occurrence of viremia and NAbs. One of the
hallmarks of PRRSV infection is the prolonged viremic phase.
Our laboratory had previously demonstrated that passive
transfer of NAbs to adult sows completely blocked the establishment of viremia to the point of reaching sterilizing conditions (33) and that young pigs with a level of circulating NAbs
sufficient to reach a titer of 1:8 in serum can protect the pigs

from viremia after challenge with a highly virulent PRRSV
strain (25). Since PRRSV-01 and FL01 mounted an early and
robust homologous NAb response, we were interested in examining the effects of these early and robust NAb responses on
the levels of viremia, as this would have significant implications
for the potential use of this strain in an immunization approach. To our surprise, viremia was still detected in all pigs
infected with PRRSV-01 as well as in those infected with FL01
at 14 day p.i. in spite of the presence of NAbs at a titer greater
than 1:8 (Table 4).
Emergence of a NAb escape mutant. On the basis of previous results reported for lactate dehydrogenase-elevating
virus (LDV), a related arterivirus (8), we reasoned that
during the process of replication in the host, the PRRSV-01
and FL01 viruses may have acquired mutations that helped
them escape the effect of NAbs. To address this possibility,
we isolated virus from a serum sample collected from one
pig that had been infected with FL01 at 14 days p.i. The
virus was designated FL01-14dpi, and the susceptibility of

TABLE 4. Viremia measured in swine
monocyte-derived macrophages
Group and
pig IDa no.

Viral titerb at the following day p.i.:
7

14

21

PRRSV-01-infected group
327
343
527
972
Mean

2.25
2.50
ND
1.75
2.17

2.25
3.25
3.00
4.75
3.31

2.75
ND
3.25
3.50
3.17

FL01-infected group
310
318
337
355
Mean

3.00
2.00
2.50
2.25
2.44

3.50
5.00
4.50
4.75
4.44

2.25
2.00
3.00
2.75
2.50

FL01/DM-infected group
311
317
322
325
Mean

5.50
4.25
5.50
4.75
5.00

1.75
4.75
4.50
1.75
3.19

2.50
ND
ND
1.75
2.13

a

ID, identification.
Viral titers at the indicated times (days) p.i. are expressed as the log10
TCID50/ml. ND, not detected.
b
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from serum samples, ORF3 and ORF5 of these viruses were
sequenced. Similar to FL01-14dpi, all of the 7 newly isolated
viruses exhibited N-glycosylation sites at the glycan-missing
positions (data not shown). In addition, we also observed an
S204P mutation in GP3 of 1 virus and a C112F mutation in
GP5 of another virus (data not shown). The rapid reappearance of N-glycosylation sites in GP3 and GP5 suggests that
there is a strong selective pressure at those sites.
DISCUSSION

FIG. 6. Emergence of antibody escape mutant. (A) FL01-14dpi was
isolated from a serum sample from a pig that had been infected with
FL01 virus at 14 days postinfection (dpi). The neutralizing activities of
serum samples from all four FL01-infected pigs at the indicated days
postinfection (PI) were measured against FL01-14dpi. Neutralization
titers are expressed as means ⫾ SEMs. Kinetics of FL01 homologous
antibody response was redrawn from Fig. 5 for comparison. (B) Mutations
in the structural genes of FL01-14dpi compared to the corresponding
genes of FL01 before infection. Amino acid changes that result in reappearance of N-glycosylation sites are shown in boldface type.

the virus to antibody neutralization was examined. As shown
in Fig. 6A, there was a great difference in the susceptibility
of FL01-14dpi and FL01 to neutralization by FL01-specific
antisera. For instance, all serum samples at 14 days p.i. were
able to neutralize FL01 with titers equal to or greater than
1:8, while none of the serum samples were able to neutralize
FL01-14dpi. At 49 days p.i., when the mean neutralization
titer against FL01 was 1:3,444, the titer against FL01-14dpi
was only 1:90. These results indicate that the virus at 14 days
p.i. (i.e., FL01-14dpi) is much more resistant to antibody
neutralization than the input virus (FL01).
To determine the mutations responsible for the resistance of
FL01-14dpi to antibody neutralization, the entire structural
region of the viral genome was sequenced. Overall, we detected a total of 4 amino acid changes (Fig. 6B). Surprisingly,
two of the amino acid changes resulted in the appearance of
N-glycosylation sites at the glycan-missing positions both in
GP3 and GP5. The results suggested that the reappearance of
N-glycosylation sites is most likely responsible for the resistance of FL01-14dpi to antibody neutralization, although the
contribution of other mutations may not be ruled out. To
determine whether the restoration of N-glycosylation sites also
happened in other pigs, seven more viruses were further isolated from serum samples at 14 days p.i., which included 3
viruses from the remaining FL01-infected pigs and 4 viruses
from PRRSV-01-infected pigs. After the viruses were isolated

Many viruses rely on glycosylation modification of their envelope glycoproteins to evade the host immune system (16, 24,
38, 44, 45). It has been demonstrated in the case of PRRSV
that N-glycans surrounding the major neutralizing epitope located in the ectodomain of GP5 protect the virus from antibody neutralization and impair the immunogenicity of the
epitope (3, 15). Although the PRRSV virion carries 4 different
glycoproteins, namely, GP2, GP3, GP4, and GP5, so far it is
not known whether the N-glycans on glycoproteins other than
GP5 were involved in immune evasion. In the present study, we
demonstrate that the N-glycan in GP3 of a type II PRRSV
isolate is as important as its counterpart in GP5 regarding its
role in protection of the virus from antibody neutralization.
GP5 of type II PRRSV contains 3 to 5 potential N-glycosylation sites, of which the N-glycosylation sites at N44 and N51
are strongly conserved, while the N-glycosylation sites upstream of N44 are variable (Fig. 2B). Our laboratory had demonstrated that FL12 mutants carrying disrupted N-glycosylation sites at N34 and N51 of GP5 were more susceptible to
antibody neutralization and elicited greater NAb responses
than did the wt FL12 strain (3). Likewise, Faaberg et al. (15)
reported that the PRRSV field isolate HV-1 naturally lacking
the N-glycosylation site(s) upstream of N44 mounted a significantly early and strong NAb response which was coincident
with the increased antibody binding to the nearby neutralizing
epitope. Surprisingly, the authors observed that another
PRRSV field isolate named N44 lacking N-glycosylation site at
position N44 did not display any enhancement in eliciting
NAbs even though this glycosylation site is located inside the
neutralizing epitope (15). In the present study, we demonstrate
that the absence of N-glycosylation site at N51 in GP5 of
PRRSV-01 also increases the susceptibility of the virus to antibody neutralization as well as enhances the ability of the virus
to mount a homologous NAb response. Collectively, the available information suggests that N-glycans located upstream of
N44 and N51 are important for the virus to escape antibody
neutralization, while the N-glycan at N44 might not be as
central to that purpose.
A remarkable observation in our study is the involvement of
an N-glycan moiety in GP3 of a type II PRRSV isolate in
interference with antibody neutralization. GP3 of PRRSV harbors 7 potential N-glycosylation sites, the highest number of
glycosylation sites compared to all the other PRRSV envelope
glycoproteins (12). Moreover, all the glycosylation sites are
strongly conserved in different type II PRRSV strains (Fig.
2A). To examine the role of N-glycosylation of minor glycoproteins in eliciting NAbs, we previously generated a series of
mutant viruses, each of which carry one glycosylation deletion
or multiple glycosylation deletions. We found that disruption
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of N-glycosylation sites at N29, N152, and N160 in GP3 of
PRRSV strain FL12 did not affect virus susceptibility to antibody neutralization as well as the ability to mount a NAb
response (12). We report herein that the absence of N-glycosylation site at N131 in GP3 of PRRSV-01 results in enhanced
neutralization susceptibility and increased NAb elicitation.
The results suggest that the relative position of the glycosylation site in the glycoprotein might be important for its ability to
modulate NAb induction.
We do not know at this time how the N-glycan at N131 in
GP3 of PRRSV-01 protects the virus from neutralization by
NAbs. There is evidence that GP3 of type II PRRSV might
contain one neutralizing epitope, but the location of this
epitope has not been mapped (6). It is therefore tempting to
speculate that the glycan moiety at N131 in GP3 may prevent
the accessibility of NAbs to an epitope located within GP3. On
the other hand, GP2, GP3, and GP4 of PRRSV interact each
other to form a multiprotein complex (11). Thus, it is also
possible that the glycan moiety in GP3 might mask the epitope
located in GP2 or GP4.
The neutralizing epitope in GP5 that we initially described
has been considered the major neutralizing epitope (34). In
this study, the susceptibility to antibody neutralization of FL01/
GP3-D131N is not significantly different from that of FL01/
GP5-S51N (Table 2). Likewise, both viruses yield similar homologous NAb titers at 49 days p.i., although there seems to be
a slight difference in the kinetics of NAb response (Fig. 5).
Together, the results indicate that the N-glycan in GP3 is as
important as the one in GP5 regarding its role in modulating
the NAb response. Therefore, this notion should be taken into
account in future PRRSV vaccine design.
The presence of glycan moieties in the viral envelope proteins not only renders the virus resistant to antibody neutralization but also impairs the ability of the virus to elicit NAb
responses. Therefore, removal of glycosylation sites increases
the susceptibility of the virus to antibody neutralization as well
as enhances the ability of the virus to elicit NAbs in vivo (3, 38).
In the present study, although all the hypoglycosylated viruses
were able to elicit homologous NAb responses greater than the
FL01/DM virus, none of them were able to elicit significantly
greater neutralization titers measured against FL01/DM (Table 3). We reason that the failure of hypoglycosylated viruses
to induce greater NAb titers against FL01/DM was due to the
rapid reappearance of glycosylation sites at the glycan-missing
positions. It is noteworthy that although the glycosylation sites
reappeared within 14 days p.i., FL01 was still able to show a
tendency to induce a greater NAb titer against FL01/DM. It is
therefore plausible to hypothesize that if the hypoglycosylated
form is stable for longer periods of time after infection, then the
pigs infected with hypoglycosylated viruses may produce greater
NAb titers to the FL01/DM than those infected with FL01/DM.
We had previously reported that removal of the N-glycosylation sites in GP3 or GP5 of the PRRSV strain FL12 severely
affected viral replication in MARC-145 cells (3, 12). In this
study, we observe the enhanced replication efficiency of
PRRSV-01 and FL01 in MARC-145 cells in spite of the absence of the N-glycosylation sites in their GP3 and GP5 (Fig.
4). The discrepancy in the effect of N-glycosylation sites on
viral replication might be due to the difference in the ways the
N-glycosylation sites are deleted. In our previous studies, the
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N-glycosylation sites in GP3 and GP5 of FL12 were artificially
removed from the genome of the virus, and presumably no
other mutations occurred (3, 12). In the current study, the
N-glycosylation sites were naturally deleted. We assume that
concomitant with the mutations leading to the removal of
N-glycosylation sites from GP3 and GP5 of PRRSV-01, other
compensational mutations also occurred which together enhance the replication of the virus in cell culture.
PRRSV-01 was isolated from a field sample submitted to the
Veterinary Diagnostic Laboratory of Iowa State University.
Immediately after isolation, the ORF5 of PRRSV-01 was sequenced as a routine surveillance (GenBank accession no.
EU556202.1). After that, the virus was propagated in MARC145 cells for multiple passages. Retrospective analysis of the
ORF5 sequence obtained at the time of isolation of the virus
revealed that the N-glycosylation site at position N51 was indeed present in the gene (data not shown). Since the ORF3
sequence of the virus right after isolation is not available, we
do not know the N-glycosylation pattern of this protein at the
time of isolation. We hypothesize that both glycosylation sites
at N131 in GP3 and N51 in GP5 of PRRSV-01 were lost during
replication of the virus in MARC-145 cells.
The rapid reappearance of N-glycosylation sites in both GP3
and GP5 of PRRSV-01 and FL01 after inoculation into pigs
suggests a strong selective pressure at these sites. It is most
likely that the host immune response is one of the major
driving forces for the restoration of the N-glycosylation sites.
In addition, the PRRSV-01 virus used in this study had
adapted to MARC-145 cells, which differ from porcine macrophage cells (i.e., the natural host cells of PRRSV) in terms of
their expression of receptors for PRRSV entry (5, 21, 42).
Thus, the different cell tropism might also contribute to the
reappearance of the N-glycosylation sites in GP3 and GP5 of
PRRSV-01 during its replication in vivo.
The natural absence of N-glycosylation sites had been observed in other viruses such as lactate dehydrogenase-elevating
virus (LDV) (8). The primary envelope glycoprotein VP-3P of
LDV strains LDV-C and LDV-v naturally lack two N-glycosylation sites compared to strains LDV-P and LDV-vx (8). Consequently, the LDV-C and LDV-v strains are much more susceptible to antibody neutralization and elicit much greater
NAb responses than the LDV-P and LDV-vx strains (8). More
importantly, the LDV-C and LDV-v strains also regained Nglycosylation sites after 2 or 3 passages in mice and became
resistant to antibody neutralization.
In summary, our results herein confirm the previous findings
that the N-glycan moieties in GP5 of type II PRRSV are
important for the virus to escape the effect of NAbs (3, 15). In
addition, we demonstrate for the first time that the N-glycan in
GP3 of type II PRRSV is also important in protecting the virus
from antibody neutralization. Likewise, the overall body of
results herein presented firmly confirms the important notion
that GP3 may be involved in inducing neutralizing antibodies,
a concept that has already been suggested by previous investigators (6, 19, 22, 37).
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